Abstract: The present invention provides indole-containing macrocyclic compounds and the uses thereof, and particularly relates to compounds represented by formula (II) or pharmaceutically acceptable salts thereof.

Abstract: Provided is an indole compound. In particular, disclosed are a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof and a use of the same as an estrogen receptor antagonist in preparing a drug for treating estrogen receptor-positive breast cancer.

Abstract: Disclosed are a non-fluorinated quinolone compound and use thereof, specifically relating to a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a pyrrolopyrazole spiro compound, and the use thereof in preparing a drug for treating related diseases. The present invention specifically relates to a compound as represented by formula (I?), and a stereoisomer and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a pyrimidinyl group-containing tricyclic compound and applications thereof in preparing a cancer-treating medicament. Specifically disclosed are a compound as represented by formula (I), a pharmaceutically acceptable salt of same, or an isomer thereof.

Abstract: The present invention discloses a crystal form of a hepatitis B surface antigen inhibitor and a preparation method therefor, and also comprises the use of the crystal form in preparing the hepatitis B surface antigen inhibitor.

Abstract: Provided are a salt form of an estrogen receptor down-regulator, a crystalline form thereof, and a preparation method therefor

Abstract: The present invention relates to a structurally novel TLR8 (Toll-like receptor 8) agonist and, in particular, to a compound thereof of formula (I), a pharmaceutically acceptable salt and an isomer thereof.

Abstract: A TLR8 (Toll-like receptor 8) agonist, a compound of the structure shown in formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.

Abstract: A bicyclic substituted aromatic carboxylic acid compound, in particular a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof. In formula (I), R2 and R3 and atoms connected thereto together form a 3-6 membered heterocyclic group, or R2 and R4 and atoms connected thereto together form a 3-6 membered heterocyclic group. The compound has obvious inhibitory activity on activation of a human serum alternative pathway and significant binding activity to human complement Factor B protein, and also has relatively good in-vivo pharmacodynamic and pharmacokinetic properties.

Abstract: Disclosed are a class of macrocyclic derivatives, a preparation method therefor, a pharmaceutical composition containing the derivatives, and the use thereof as therapeutic agents, particularly as XIa factor inhibitors and in the preparation of a drug for treating and preventing thromboembolisms and other diseases. Particularly disclosed are compounds shown by formula (I), an isomer thereof and a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a series of substituted pyridine-2,4-dione derivatives and preparation methods therefor, and in particular, to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is an aminopyrimidine compound as a CDK2/4/6 inhibitor, and specifically disclosed are the compound represented by formula (I) and a pharmaceutically acceptable salt thereof, and an application of the compound represented by formula (I) and the pharmaceutically acceptable salt thereof in the preparation of a medicament for treating solid tumor.

Abstract: An indoline compound. Specifically disclosed is an application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in the preparation of drugs for treating related diseases.

Abstract: A salt form of a tetra-substituted olefin compound, a crystal of the compound and the salt, and a preparation method relating to a crystal of a compound represented by formula (I), a salt thereof, a crystal of the salt thereof, and a preparation method therefor.

Abstract: The present application relates to a novel conjugate group linkable to a compound (such as a therapeutic compound), for use in directing the compound to a target in the body. The conjugate group disclosed herein can enable an expression-inhibitory oligonucleotide (such as a RNAi reagent) to target liver cells to regulate gene expression. The conjugate group disclosed herein has a variety of applications when linked to expression-inhibitory oligonucleotides, comprising applications in therapy, diagnosis, target verification, and genome development. A composition comprising the conjugate group disclosed herein can mediate expression of target nucleic acid sequences in liver cells (such as hepatocytes) when linked to expression-inhibitory oligonucleotides, and can be used for treatment of diseases or disorders responding to the gene expression or activity of cells, tissues, or organisms.

Abstract: Disclosed are a salt form used as a CDC7 inhibitor and a crystal form thereof, and specifically disclosed is a compound represented by formula (II), a crystal form thereof, a preparation method thereof, and an application thereof in the preparation of a drug for preventing or treating tumors.

Abstract: Disclosed is a crystal form of a hepatitis B surface antigen inhibitor and a preparation method, and an application of the crystal form in the preparation of the hepatitis B surface antigen inhibitor.

Abstract: Provided is an isochroman compound represented by formula (I), or a pharmaceutically acceptable salt thereof, which is used as an aldo-keto reductase (AKR1C3) inhibitor for the treatment of liver cancer.

Abstract: Disclosed is a type of indolo heptamyl oxime analog crystalline form as a PARP inhibitor and a method for preparing the same, specifically relating to a crystalline form of a compound of formula (I) and a method for preparing the same.